The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, M. D.
Right arrow Articles by Watts, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, M. D.
Right arrow Articles by Watts, T. H.

The Journal of Immunology, Vol 157, Issue 7 2837-2843, Copyright © 1996 by American Association of Immunologists


ARTICLES

Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition

MD Goldstein and TH Watts
Department of Immunology, University of Toronto, Ontario, Canada.

Binding of CD40 ligand to CD40 on a murine B lymphoma M12 induces B7-1 and inhibits cell growth. We have used M12 lymphomas transfected with wild-type and mutant human CD40 molecules to identify regions of the CD40 cytoplasmic tail involved in these signal transduction events. We find that threonine residues at positions 227 and 234 in the cytoplasmic domain play important role in B7-1 induction, but have lesser importance in CD40-mediated growth inhibition. In contrast, a deletion mutant with only six amino acids in the cytoplasmic tail retains some growth-inhibitory function, but has no detectable B7-1 induction capacity. We also find that cAMP synergizes with CD40 signaling to induce high level B7-1 induction, and that the synergistic signal through CD40 requires either T227 or T234, but not both. Thus, we provide evidence for at least two distinct signaling domains in the CD40 molecule.


This article has been cited by other articles:


Home page
J. Immunol.Home page
B. O. Lee, J. Moyron-Quiroz, J. Rangel-Moreno, K. L. Kusser, L. Hartson, F. Sprague, F. E. Lund, and T. D. Randall
CD40, but Not CD154, Expression on B Cells Is Necessary for Optimal Primary B Cell Responses
J. Immunol., December 1, 2003; 171(11): 5707 - 5717.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L.-F. Lu, W. J. Cook, L.-L. Lin, and R. J. Noelle
CD40 Signaling through a Newly Identified Tumor Necrosis Factor Receptor-associated Factor 2 (TRAF2) Binding Site
J. Biol. Chem., November 14, 2003; 278(46): 45414 - 45418.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Suvas, V. Singh, S. Sahdev, H. Vohra, and J. N. Agrewala
Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma
J. Biol. Chem., March 1, 2002; 277(10): 7766 - 7775.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. D. Erickson, T. M. Foy, and T. J. Waldschmidt
Murine B1 B Cells Require IL-5 for Optimal T Cell-Dependent Activation
J. Immunol., February 1, 2001; 166(3): 1531 - 1539.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. G. Eliopoulos, C. Davies, P. G. Knox, N. J. Gallagher, S. C. Afford, D. H. Adams, and L. S. Young
CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily
Mol. Cell. Biol., August 1, 2000; 20(15): 5503 - 5515.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
B. Segui, N. Andrieu-Abadie, S. Adam-Klages, O. Meilhac, D. Kreder, V. Garcia, A. P. Bruno, J.-P. Jaffrezou, R. Salvayre, M. Kronke, et al.
CD40 Signals Apoptosis through FAN-regulated Activation of the Sphingomyelin-Ceramide Pathway
J. Biol. Chem., December 24, 1999; 274(52): 37251 - 37258.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. S. Pullen, T. T. A. Dang, J. J. Crute, and M. R. Kehry
CD40 Signaling through Tumor Necrosis Factor Receptor-associated Factors (TRAFs). BINDING SITE SPECIFICITY AND ACTIVATION OF DOWNSTREAM PATHWAYS BY DISTINCT TRAFs
J. Biol. Chem., May 14, 1999; 274(20): 14246 - 14254.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. L. Sutherland, D. L. Krebs, and M. R. Gold
An 11-Amino Acid Sequence in the Cytoplasmic Domain of CD40 Is Sufficient for Activation of c-Jun N-Terminal Kinase, Activation of MAPKAP Kinase-2, Phosphorylation of I{kappa}B{alpha}, and Protection of WEHI-231 Cells from Anti-IgM-Induced Growth Arrest
J. Immunol., April 15, 1999; 162(8): 4720 - 4730.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. v. Leoprechting, P. van der Bruggen, H. L. Pahl, A. Aruffo, and J. C. Simon
Stimulation of CD40 on Immunogenic Human Malignant Melanomas Augments Their Cytotoxic T Lymphocyte-mediated Lysis and Induces Apoptosis
Cancer Res., March 1, 1999; 59(6): 1287 - 1294.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
J. D. Pound, A. Challa, M. J. Holder, R. J. Armitage, S. K. Dower, W. C. Fanslow, H. Kikutani, S. Paulie, C. D. Gregory, and J. Gordon
Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells
Int. Immunol., January 1, 1999; 11(1): 11 - 20.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. C. Grammer, J. L. Swantek, R. D. McFarland, Y. Miura, T. Geppert, and P. E. Lipsky
TNF Receptor-Associated Factor-3 Signaling Mediates Activation of p38 and Jun N-Terminal Kinase, Cytokine Secretion, and Ig Production Following Ligation of CD40 on Human B Cells
J. Immunol., August 1, 1998; 161(3): 1183 - 1193.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Purkerson and D. C. Parker
Differential Coupling of Membrane Ig and CD40 to the Extracellularly Regulated Kinase Signaling Pathway
J. Immunol., March 1, 1998; 160(5): 2121 - 2129.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.